Sleep in Parkinson's disease.
Two major sources of dissatisfaction with the quality of life among Parkinsonian patients are the "locomotor disability" and the "nature of their sleep". The main focus of research was directed towards the locomotor disability, but in the last two decades some progress has been made towards the understanding of sleep in PD patients. Sleep in Parkinson's disease is light and fragmented due to an increased skeletal muscle activity, disturbed breathing, impaired biological rhythm and REM-nonREM variations of the dopaminergic receptor sensitivity.
Askenasy
J J
JJ
Sleep Research Institute, Sheba Medical Center, Tel-Aviv University, Israel.
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001683:Biological Clocks / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000627:therapeutic use; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy / Q000503:physiopathology; D012894:Sleep Stages / Q000187:drug effects / Q000502:physiology*; D012895:Sleep, REM / Q000187:drug effects / Q000502:physiology
D000978:Antiparkinson Agents; D006993:Hypnotics and Sedatives